Welcome to our dedicated page for LAVA Therapeutics N.V. Ordinary Shares news (Ticker: LVTX), a resource for investors and traders seeking the latest updates and insights on LAVA Therapeutics N.V. Ordinary Shares stock.
LAVA Therapeutics N.V. (Nasdaq: LVTX) is a pioneering biotechnology company that specializes in transforming cancer treatment through its innovative Gammabody® platform. This platform harnesses bispecific gamma-delta T cell engagers designed to target and eliminate cancer cells. The company focuses on both solid tumors and hematologic malignancies, aiming to deliver groundbreaking therapies for patients with unmet medical needs.
One of LAVA's lead programs is LAVA-1207, which targets the prostate-specific membrane antigen (PSMA) to treat metastatic castration-resistant prostate cancer (mCRPC). This program has shown a favorable safety profile and preliminary signs of anti-tumor activity in ongoing Phase 1/2a clinical trials across Europe and the United States. Recently, LAVA announced a collaboration with Merck & Co., Inc., Rahway, NJ, USA to evaluate LAVA-1207 in combination with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab).
In addition to LAVA-1207, the company is advancing other promising candidates such as PF-08046052, formerly known as LAVA-1223, which targets EGFR-positive tumors and is being developed under a license agreement with Pfizer. LAVA is also preparing an IND submission for LAVA-1266, a treatment targeting CD123 for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Financially, LAVA is well-positioned, with a focus on extending its cash runway into 2026 through strategic prioritization of its pipeline. The company has formed valuable collaborations, including partnerships with Seagen and Pfizer, to advance its clinical programs and support its growth trajectory.
For more detailed information on LAVA Therapeutics, visit their official website at www.lavatherapeutics.com and follow them on LinkedIn, X (formerly Twitter), and YouTube.
LAVA Therapeutics, a clinical-stage immuno-oncology company focused on bispecific gamma delta T cell engagers, announced that CEO Stephen Hurly will present at the Jefferies London Healthcare Conference.
The presentation is scheduled for November 17, 2022, from 8:00 a.m. to 8:30 a.m. GMT (3:00 a.m. to 3:30 a.m. EST). A webcast will be available in the investor relations section of their website and archived for 90 days afterward.
LAVA Therapeutics (Nasdaq: LVTX) announced it will present updated data from its ongoing Phase 1/2a clinical trial of LAVA-051 at the ASH Annual Meeting, December 10-13, 2022. This data will include safety, pharmacodynamics, and pharmacokinetics, along with first results from subcutaneous administration and updates on intravenous dosing cohorts. The lead candidate targets relapsed/refractory multiple myeloma and chronic lymphocytic leukemia. The presentation is scheduled for December 10, 2022, by Arnon P. Kater, M.D., Ph.D.
LAVA Therapeutics, a clinical-stage immuno-oncology company (Nasdaq: LVTX), has appointed Fred M. Powell as its new Chief Financial Officer effective immediately. Mr. Powell brings over 20 years of CFO experience in the biopharmaceutical sector, including significant roles in investor relations and strategic planning. Previously, he led the financial team at Antares Pharma, contributing to its successful $1 billion acquisition. CEO Stephen Hurly welcomed Powell, highlighting his expertise in driving growth initiatives crucial for LAVA's bispecific gamma delta T cell engagers pipeline, particularly LAVA-051 and LAVA-1207.
LAVA Therapeutics (Nasdaq: LVTX) has announced it will present clinical data for LAVA-051 during the Society for Immunotherapy of Cancer’s 37th Annual Meeting from November 8-12, 2022. The presentation will focus on the mechanism of action of LAVA-051, a bispecific gamma delta T cell engager, confirming pharmacodynamics in a clinical setting. Chief Medical Officer Benjamin Winograd will present the findings on November 11, 2022.
LAVA’s Gammabody™ platform aims to treat solid and hematological malignancies.
Seagen and LAVA Therapeutics have entered an exclusive license agreement for LAVA-1223, a bispecific T cell engager targeting EGFR-expressing solid tumors. LAVA will receive a $50 million upfront payment and could earn up to $650 million in potential milestones, plus royalties on future sales. This partnership allows Seagen to enhance its targeted cancer therapy portfolio while LAVA aims to validate its Gammabody™ platform. LAVA-1223 is designed to activate Vγ9Vδ2 T cells to improve immune response against tumors.
Seagen has entered an exclusive license agreement with LAVA Therapeutics to develop and commercialize LAVA-1223, a bispecific T cell engager targeting EGFR-expressing solid tumors. LAVA will receive an upfront payment of
LAVA Therapeutics N.V. (Nasdaq: LVTX) reported encouraging initial Phase 1/2a clinical findings for LAVA-051 targeting chronic lymphocytic leukemia and multiple myeloma, highlighting anti-tumor activity and safety. The company has a cash position of $110.7 million as of June 30, 2022, expected to fund operations for approximately two years. Ongoing trials for LAVA-1207 in metastatic castration-resistant prostate cancer are also progressing, with additional clinical data anticipated in Q4 2022.
LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical stage immuno-oncology company, announced that its CEO Stephen Hurly will present at the H.C. Wainwright 24th Annual Global Investment Conference. The virtual presentation is scheduled for September 12, 2022, and will be available for on-demand viewing starting at 7:00 a.m. EDT. Investors can access the webcast through the investor relations section on LAVA Therapeutics' website, where a replay will be available for 90 days.
The company is focused on developing bispecific gamma delta T cell engagers through its proprietary Gammabody™ platform.
LAVA Therapeutics hosted a clinical update call on June 16, 2022, focusing on the promising Phase 1/2a clinical trial data of LAVA-051, a bispecific gamma delta T cell engager, for treating chronic lymphocytic leukemia (CLL) and multiple myeloma (MM). Initial data presented at the 2022 ASCO and EHA meetings show early signs of anti-tumor activity and an appealing safety profile. The trial's primary objectives include evaluating safety and determining the recommended Phase 2 dose, with additional cohorts being enrolled in Europe and the U.S.
LAVA Therapeutics N.V. (Nasdaq: LVTX) announced the appointments of James Noble and Jay Backstrom, M.D. as non-executive directors on June 15, 2022. The appointments aim to enhance the company's clinical development and regulatory affairs expertise as it advances clinical trials for hematologic and metastatic prostate cancers. The company also announced the departure of three board members, including co-founder Erik van den Berg. Noble and Backstrom bring extensive leadership experience from other biopharmaceutical firms, potentially benefiting LAVA's ongoing Gammabody development.
FAQ
What is the current stock price of LAVA Therapeutics N.V. Ordinary Shares (LVTX)?
What is the market cap of LAVA Therapeutics N.V. Ordinary Shares (LVTX)?
What is LAVA Therapeutics N.V.?
What is the Gammabody® platform?
What is LAVA-1207?
What recent achievements has LAVA Therapeutics made?
Who are LAVA Therapeutics' key partners?
Where are LAVA Therapeutics' clinical trials conducted?
What is PF-08046052?
What is the financial outlook for LAVA Therapeutics?
How does LAVA-1207 work?
Where can I find more information about LAVA Therapeutics?
